Mirae Asset Global Investments
PRLD icon

Mirae Asset Global Investments’s Prelude Therapeutics PRLD Stock Holding History

Mirae Asset Global Investments’s Portfolio PRLD Stock Details PRLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-10,087
Closed -$45.4K – 2629
2023
Q2 		$45.4K Buy
+10,087
New +$60.3K ﹤0.01% 2596

Other funds holding PRLD

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

Mirae Asset Global Investments's PRLD Position: Q3 2023 in Review

Mirae Asset Global Investments sold out of Prelude Therapeutics (PRLD) in Q3 2023, closing a stake of 10,087 shares — an estimated $45.4K sold.

Mirae Asset Global Investments first reported a position in PRLD in Q2 2023 and held it in 1 quarter. The position peaked at $45.4K in Q2 2023. 60 funds tracked by Wall St. Rank hold PRLD as of Q3 2023.

  • Mirae Asset Global Investments reported no remaining Prelude Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Mirae Asset Global Investments sold 10,087 Prelude Therapeutics shares in Q3 2023, an estimated $45.4K.
  • Mirae Asset Global Investments first reported a position in Prelude Therapeutics in Q2 2023 and held it in 1 quarter.
  • Mirae Asset Global Investments's Prelude Therapeutics position peaked at $45.4K in Q2 2023.
  • 60 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q3 2023.

Based on Mirae Asset Global Investments's 13F filing for Q3 2023, filed 26 Oct 2023.